Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026)
Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
34.98% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-46.86% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
33.54% |
| Date | Value |
|---|
| Mar 31, 2026 |
33.54% |
| Dec 31, 2025 |
0.62% |
| Sep 30, 2025 |
26.43% |
| Jun 30, 2025 |
-7.80% |
| Mar 31, 2025 |
17.18% |
| Dec 31, 2024 |
30.78% |
| Sep 30, 2024 |
14.90% |
| Jun 30, 2024 |
14.14% |
| Mar 31, 2024 |
35.28% |
| Dec 31, 2023 |
-0.97% |
| Sep 30, 2023 |
16.75% |
| Jun 30, 2023 |
28.67% |
| Mar 31, 2023 |
-51.80% |
| Dec 31, 2022 |
10.35% |
| Sep 30, 2022 |
-21.18% |
| Jun 30, 2022 |
17.26% |
| Mar 31, 2022 |
-27.91% |
| Dec 31, 2021 |
-2.70% |
| Sep 30, 2021 |
-17.94% |
| Jun 30, 2021 |
-76.53% |
